Merck Stock News

American Research & Management Co. reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 1.8% during the third quarter, Holdings Channel.com reports. The firm owned 19,221 shares of the companys stock after selling 350 shares during the period. American Research & Management Co.s holdings in Merck & Co., Inc. were worth $1,444,000 []

While the Food and Drug Administration (FDA) is expected to soon rule on whether to authorize Merck''s COVID-19 pill, questions remain regarding its risks in pregnant women.

The Common Cancer-associated Antigens (CAAs) Vaccine research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and

Dublin, Dec. 15, 2021 (GLOBE NEWSWIRE) -- The "Methicillin-Resistant Staphylococcus Aureus Drugs Market Research Report by Drug Class, MOA, Drug Origin, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com''s offering. The Global Methicillin-Resistant Staphylococcus Aureus Drugs Market size was estimated at USD 1,542.93 million in 2020, is expected to reach USD 1,623.64 million in 2021, and projected to grow at a CAGR of 5.56% reaching USD 2,135.87 million by 2026. Market Statistics

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--European Commission Approves Mercks VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older

Pfizer''s Cvid-19 drug is almost 90% effective in preventing hospitalization or death in high-risk patients, according to a recent study by the world''s news agencies. The results were announced by the manufacturer. Pfizer also said that laboratory tests suggested that the pill also worked against the rapidly spreading Omicron variant of the coronavirus. The US company said last month that the drug was about 89% effective in preventing hospitalization or death when compared to a placebo in nearly 1,200 volunteers. Another 1,000 people took part in the new study, which was presented today. None of the volunteers treated with Pfizer died, and there were twelve deaths in the placebo group. The company''s medicine was taken in combination with the antiviral drug ritonavir every 12 hours for five days, starting shortly after the onset of symptoms of Covid-19. If approved, the medicine will be sold as Paxlovid. Pfizer also presented initial data from a second clinical trial, which showed that treatment with Covid-19 reduced hospitalizations by about 70% in nearly 600 adults at standard risk. "This is a stunning result," said Mikael Dolsten, the company''s chief scientific officer.

Key Players covered in the Antiviral Drugs Market Research Report are Abbvie, Inc., Novartis AG, Gilead Sciences, Mylan N.V., GlaxoSmithKline, Merck & Co., Inc., Janssen Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Other key market players. Key Players covered in the Antiviral Drugs Market Research Report are Abbvie, Inc., Novartis AG, Gilead Sciences, Mylan N.V., GlaxoSmithKline, Merck & Co., Inc., Janssen Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Other key market players.

Related Stocks: SNY , AZN , ABBV , NVS , MRK , VTRS ,

(RTTNews) - German drug giant Merck KgaA (MKGAY.PK) said that it has signed an agreement with biotechnology company Innovative Biotech to design the manufacturing process for the first vaccine production facility in Nigeria. The collaboration is part of the West African pandemic readiness program, which aims to localize vaccine development in

NEW YORK - Stocks that traded heavily or had substantial price changes Tuesday: Merck & Co., up 99 cents to $73.72. The Food and Drug Administration placed a hold on the

Mercer Capital Advisers Inc. decreased its holdings in Merck & Co., Inc. (NYSE:MRK) by 2.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,900 shares of the companys stock after selling 1,925 shares during the period. Merck & Co., Inc. comprises approximately 2.6% of []

Davy Global Fund Management Ltd lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 0.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 102,276 shares of the companys stock after selling 729 shares during the period. Merck & Co., Inc. []

Cape Canaveral, FL, Dec. 14, 2021 (GLOBE NEWSWIRE) -- SpaceXs upcoming 24th Commercial Resupply Services (CRS) mission to the International Space Station (ISS) will include more than 15 payloads sponsored by the ISS National Laboratory, managed by the Center for the Advancement of Science in Space, Inc. (CASIS). These payloads include multiple investigations from private-sector entities, including two supported by highly recognizable companies: Merck and Procter & Gamble.